We previously showed that NF-κB/BRD4-mediated transcription of IL6 and BIRC5 presents a pathway of resistance to tyrosine kinase inhibitors (TKIs) in heterogenous GBM models (16). The gene discussed is IL6; the disease is glioblastoma.